20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T1703 | SN-38 | NK012,SN 38 | DNA/RNA Synthesis , Topoisomerase , Autophagy |
SN-38 (NK012) is the active metabolite of Irinotecan, a DNA topoisomerase I (Topo I) inhibitor, which inhibits DNA and RNA synthesis (IC50=0.077/1.3 μM). SN-38 has antitumor activity and induces autophagy. | |||
T17731L | CL2A-SN-38 DCA 1279680-68-0(free base) | Others | |
CL2A-SN-38 is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC).. CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibito... | |||
T17731 | CL2A-SN-38 | Others | |
CL2A-SN-38 is a drug-linker conjugate consisting of SN-38, a potent DNA topoisomerase I inhibitor, and linker CL2A, for the manufacture of antibody drug conjugates (ADCs). CL2A-SN-38 provides significant and specific ant... | |||
T10832 | CL2-SN-38 | Others | |
CL2-SN-38, a part of the antibody-drug conjugate (ADC), can conjugate with the anti-Trop-2-humanized antibody hRS7. SN-38 is an inhibitor of DNA topoisomerase I. | |||
T18538 | MAC glucuronide phenol-linked SN-38 | Others | |
MAC glucuronide phenol-linked SN-38, a pH-sensitive lactone and DNA topoisomerase I inhibitor drug linker, exhibits cytotoxicity in L540cy and Ramos cells, with IC50 values of 113 ng/mL and 67 ng/mL, respectively[1]. | |||
T18722 | MAC glucuronide α-hydroxy lactone-linked SN-38 | Others | |
MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a cytotoxic drug linker that maintains a stabilized lactone form, showing efficacy against L540cy and Ramos cells, with IC50 values of 99 and ... | |||
T39222 | Mc-VC-PAB-SN38 | Mc-VC-PAB-SN38 | Others |
Mc-VC-PAB-SN38 consists of a cleavable ADC linker (Mc-VC-PAB) and SN38, which is part of an antibody-coupled reactive molecule commonly used to synthesize antibody-coupled reactive molecules (ADCs) that target sites of a... | |||
T73905 | SN-38 glucuronide | ||
SN-38 glucuronide, an inactive metabolite of Irinotecan, serves as a derivative of this cancer-fighting agent. Irinotecan, known for inhibiting topoisomerase I, is utilized in the research of colon and rectal cancer [1]. | |||
T38962 | MC-SN38 | MC-SN38 | |
MC-SN38 is a drug-linker conjugate that pairs the potent microtubule-disrupting agent SN38 with a non-cleavable MC linker, designed for use in antibody drug conjugates (ADCs). SN38, the active metabolite of the Topoisome... | |||
T4595 | YHO-13177 | YHO 13177,YHO13177 | BCRP |
YHO-13177 is a potent and specific inhibitor of BCRP; potentiated the cytotoxicity of SN-38 in cancer cells and no effect on P-glycoprotein–mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells. | |||
T0486L | Irinotecan Hydrochloride | Camptothecin 11 hydrochloride,CPT-11 hydrochloride | Topoisomerase , Autophagy |
Irinotecan Hydrochloride (CPT-11 hydrochloride) is the hydrochloride salt of a semisynthetic derivative of camptothecin. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptoth... | |||
T6S1559 | Aurantio-obtusin | Others | |
1. Biotransformation of glucoAurantio-obtusin towards Aurantio-obtusin increased the toxicity of irinotecan through increased inhibition of SN-38 glucuronidation. 2. Aurantio-obtusin, stimulated chemotactic migration of ... | |||
TQ0260 | Cerulenin | Antibiotic , Antifungal , Fatty Acid Synthase | |
Cerulenin is a natural inhibitor of fatty acid synthase (FAS). It is produced by the fungus Cephalosporium caeruleus. | |||
T82710 | CL2E-SN38 | ||
CL2E-SN-38 is a structurally stable and highly releasable antibody-drug conjugate (ADC) incorporating SN-38, the active metabolite of Irinotecan and a potent Topoisomerase I inhibitor [1] from the camptothecins class. | |||
T77837 | CL2E-SN38 TFA | ||
CL2E-SN-38 TFA, a structurally stable and highly releasable antibody drug conjugate (ADC), comprises SN-38, the active metabolite of Irinotecan derived from camptothecins, known for its Topoisomerase I inhibitory activit... | |||
T25593 | Labetuzumab govitecan | IMMU-130,Labetuzumab-SN38,hMN14-SN38,IMMU130,IMMU 130 | Others |
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer. | |||
T17730 | CL2 Linker | Others | |
CL2 Linker is a cleavableADC linker. CL2-SN-38 and CL2A-SN-38 are equivalent in drug substitution (~6), cell binding (Kd ~1.2 nM), cytotoxicity (IC50 ~2.2 nM), and serum stability in vitro (t1/2 ~20 hours)[1][2]. | |||
T38474 | CL2-MMT-SN38 | CL2-MMT-SN38 | |
CL2-MMT-SN38 is a derivative of SN-38, which is a potent anticancer agent and the active metabolite of Irinotecan (CPT-11), a Topoisomerase I inhibitor. | |||
T77824 | Sacituzumab govitecan | IMMU-132 | |
Sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, facilitates the delivery of SN-38. It demonstrates anticancer activity [1]. | |||
T70577 | PEN-866 | ||
PEN-866 is a potential agent for controlling early stage tumor growth for non-small cell lung cancer (NSCLC). PEN-866 is a novel esterase-cleavable conjugate of an HSP90i and a topoisomerase I inhibitor, SN-38 |